Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Nurika Assanzhanova"'
Autor:
Kamshat Shorayeva, Aziz Nakhanov, Ainur Nurpeisova, Olga Chervyakova, Kuanysh Jekebekov, Zhandos Abay, Nurika Assanzhanova, Sandugash Sadikaliyeva, Elina Kalimolda, Aibol Terebay, Sabina Moldagulova, Zharkinay Absatova, Ali Tulendibayev, Syrym Kopeyev, Gulnur Nakhanova, Aisha Issabek, Sergazy Nurabayev, Aslan Kerimbayev, Lespek Kutumbetov, Yergali Abduraimov, Markhabat Kassenov, Mukhit Orynbayev, Kunsulu Zakarya
Publikováno v:
Vaccines, Vol 11, Iss 12, p 1771 (2023)
Creating an effective and safe vaccine is critical to fighting the coronavirus infection successfully. Several types of COVID-19 vaccines exist, including inactivated, live attenuated, recombinant, synthetic peptide, virus-like particle-based, DNA an
Externí odkaz:
https://doaj.org/article/61ec8e64110c4ec2aa11e3303deeeed9
Autor:
Ainur Nurpeisova, Berik Khairullin, Ruslan Abitaev, Kamshat Shorayeva, Kuanish Jekebekov, Elina Kalimolda, Aslan Kerimbayev, Karligash Akylbayeva, Zhandos Abay, Balzhan Myrzakhmetova, Aziz Nakhanov, Zharkinay Absatova, Sergazy Nurabayev, Mukhit Orynbayev, Nurika Assanzhanova, Khairulla Abeuov, Lespek Kutumbetov, Markhabat Kassenov, Yergaly Abduraimov, Kunsulu Zakarya
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 18, Iss 5 (2022)
This article describes the results of a preclinical safety and immunogenicity study of QazCovid-in®, the first COVID-19 vaccine developed in Kazakhstan, on BALB/c mice, rats, ferrets, Syrian hamsters and rhesus macaques (Macaca mulatta). The study
Externí odkaz:
https://doaj.org/article/5ad1a52732d14c0ab5fbc7000b284a8c
Autor:
Berik Khairullin, Kunsulu Zakarya, Mukhit Orynbayev, Yergali Abduraimov, Markhabat Kassenov, Gulbanu Sarsenbayeva, Kulyaisan Sultankulova, Olga Chervyakova, Balzhan Myrzakhmetova, Aziz Nakhanov, Ainur Nurpeisova, Kuandyk Zhugunissov, Nurika Assanzhanova, Sergazy Nurabayev, Aslan Kerimbayev, Zakir Yershebulov, Yerbol Burashev, Ilyas Kulmagambetov, Timur Davlyatshin, Maria Sergeeva, Zhanna Buzitskaya, Marina Stukova, Lespek Kutumbetov
Publikováno v:
EClinicalMedicine, Vol 50, Iss , Pp 101526- (2022)
Summary: Background: Vaccination remains the primary measure to prevent the spread of the SARS-CoV-2 virus, further necessitating the use of effective licensed vaccines. Methods: From Dec 25, 2020, to July 11, 2021, we conducted a multicenter, random
Externí odkaz:
https://doaj.org/article/d50775b3823546d192881db931e905e3
Autor:
Dina Bugybayeva, Zhailaubay Kydyrbayev, Nadezhda Zinina, Nurika Assanzhanova, Bolat Yespembetov, Yerken Kozhamkulov, Kunsulu Zakarya, Sholpan Ryskeldinova, Kaissar Tabynov
Publikováno v:
Infectious Diseases of Poverty, Vol 10, Iss 1, Pp 1-10 (2021)
Abstract Background A new candidate vector vaccine against human brucellosis based on recombinant influenza viral vectors (rIVV) subtypes H5N1 expressing Brucella outer membrane protein (Omp) 16, L7/L12, Omp19 or Cu–Zn SOD proteins has been develop
Externí odkaz:
https://doaj.org/article/8aba2cd3013e419caa0f6e55a4ebcb48
Autor:
Kuandyk Zhugunissov, Kunsulu Zakarya, Berik Khairullin, Mukhit Orynbayev, Yergali Abduraimov, Markhabat Kassenov, Kulyaisan Sultankulova, Aslan Kerimbayev, Sergazy Nurabayev, Balzhan Myrzakhmetova, Aziz Nakhanov, Ainur Nurpeisova, Olga Chervyakova, Nurika Assanzhanova, Yerbol Burashev, Muratbay Mambetaliyev, Moldir Azanbekova, Syrym Kopeyev, Nurlan Kozhabergenov, Aisha Issabek, Moldir Tuyskanova, Lespek Kutumbetov
Publikováno v:
Frontiers in Microbiology, Vol 12 (2021)
In March 2020, the first cases of the human coronavirus disease COVID-19 were registered in Kazakhstan. We isolated the SARS-CoV-2 virus from clinical materials from some of these patients. Subsequently, a whole virion inactivated candidate vaccine,
Externí odkaz:
https://doaj.org/article/e6566ebc4b064a139619de8c493998fe
Autor:
Sholpan Ryskeldinova, Nadezhda Zinina, Zhailaubay Kydyrbayev, Bolat Yespembetov, Yerken Kozhamkulov, Dulat Inkarbekov, Nurika Assanzhanova, Aigerim Mailybayeva, Dina Bugybayeva, Makhpal Sarmykova, Berik Khairullin, Kairat Tabynov, Aitbay Bulashev, Batyrbek Aitzhanov, Khairulla Abeuov, Abylay Sansyzbay, Tlektes Yespolov, Gourapura J. Renukaradhya, Steven Olsen, Angel Oñate, Kaissar Tabynov
Publikováno v:
Frontiers in Cellular and Infection Microbiology, Vol 11 (2021)
A novel influenza viral vector based Brucella abortus vaccine (Flu-BA) was introduced for use in cattle in Kazakhstan in 2019. In this study, the safety and efficacy of the vaccine was evaluated in male and female cattle at different ages, and during
Externí odkaz:
https://doaj.org/article/784af5d432594b998f20c7744699fd56
Autor:
Sholpan Ryskeldinova, Zhailaubay Kydyrbayev, Dina Bugybayeva, Kaissar Tabynov, Yerken Kozhamkulov, Bolat Yespembetov, Nurika Assanzhanova, Nadezhda Zinina, Kunsulu Zakarya
Publikováno v:
Infectious Diseases of Poverty, Vol 10, Iss 1, Pp 1-10 (2021)
Infectious Diseases of Poverty
Infectious Diseases of Poverty
Background A new candidate vector vaccine against human brucellosis based on recombinant influenza viral vectors (rIVV) subtypes H5N1 expressing Brucella outer membrane protein (Omp) 16, L7/L12, Omp19 or Cu–Zn SOD proteins has been developed. This
Autor:
K. K. Jekebekov, Kairat Tabynov, A. Mailybayeva, Technologies, Jelgava city, Latvia, A. Valdovska, A. S. Nurpeisova, R. T. Abitayev, Zh. Kydyrbayev, D. A. Inkarbekov, Nurika Assanzhanova, M. M. Kassenov, Berik Khairullin, Y. M. Kozhamkulov
Publikováno v:
Izvestiâ Nacionalʹnoj akademii nauk Respubliki Kazahstan. 2:47-53
Autor:
Muratbay Mambetaliyev, Syrym Kopeyev, Moldir Azanbekova, Kulyaisan Sultankulova, Aziz Nakhanov, Nurlan Kozhabergenov, Olga V. Chervyakova, Markhabat Kassenov, Yerbol Burashev, Sergazy Nurabayev, Balzhan Myrzakhmetova, Kuandyk Zhugunissov, Lespek Kutumbetov, Kunsulu Zakarya, Ainur Nurpeisova, Moldir Tuyskanova, Mukhit Orynbayev, Berik Khairullin, Nurika Assanzhanova, Aslan Kerimbayev, Yergali Abduraimov, Aisha Issabek
Publikováno v:
Frontiers in Microbiology, Vol 12 (2021)
Frontiers in Microbiology
Frontiers in Microbiology
In March 2020, the first cases of human coronavirus infection COVID-19 were registered in Kazakhstan. We isolated the SARS-CoV-2 virus from the clinical material from the patients. Subsequently, a whole virion inactivated candidate vaccine, QazCovid-
Autor:
Dina Bugybayeva, Kunsulu Zakarya, Zhailaubay Kydyrbayev, Bolat Yespembetov, Yerken Kozhamkulov, Sholpan Ryskeldinova, Nadezhda Zinina, Nurika Assanzhanova, Kaissar Tabynov
Background: A new candidate vector vaccine against human brucellosis based on recombinant influenza viral vectors (rIVV) subtypes H5N1 expressing Brucella Omp16, L7/L12, Omp19 or Cu-Zn SOD proteins has been developed. This paper presents the results
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::05066be49eb68e57f3f64c78c263758b
https://doi.org/10.21203/rs.3.rs-56762/v1
https://doi.org/10.21203/rs.3.rs-56762/v1